BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects

Reuters

Jan 03, 2025

BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects

** Brokerage H.C. Wainwright raises PT on drug developer OptiNose OPTN.O to $18 from $5, maintains "buy" rating

** New PT is a 168.7% upside to the stock's Thursday close

** On Dec. 26, 2024, OPTN announced 1-for-15 reverse stock split, citing the need to meet Nasdaq's minimum bid price requirement

** Brokerage says co's nasal spray, Xhance, provides a "differentiated" fluticasone propionate treatment for chronic rhinosinusitis $(CRS)$ patients

** CRS is a long-term sinus and nasal passage inflammation caused by infections or nasal polyps

** Brokerage says "targeted education and commercial efforts" needed to increase Xhance adoption among ENT and allergy specialists

** Current focus is on 3 mln CRS patients treated by ENT and allergy specialists, with potential to reach 7 mln in primary care and 20 mln overall in the U.S. - H.C. Wainwright

** Brokerage forecasts OPTN's 2024 net revenue at $77.3 mln

** OPTN declined 64.4% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2500115399"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500115399\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2500115399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-03 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500115399","market":"us","top_or_hot":-1,"title":"BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects</title></head><body><p>** Brokerage H.C. Wainwright raises PT on <span>drug developer </span>OptiNose <span>OPTN.O</span> to $18 from $5, maintains \"buy\" rating</p><p>** New PT is a 168.7% upside to the stock's Thursday close</p><p>** On Dec. 26, 2024, OPTN announced <span>1-for-15</span> reverse stock split, citing the need to meet Nasdaq's minimum bid price requirement</p><p>** Brokerage says co's nasal spray, Xhance, provides a \"differentiated\" fluticasone propionate treatment for chronic rhinosinusitis <a href=\"https://laohu8.com/S/CRS\">$(CRS)$</a> patients</p><p>** CRS is a long-term sinus and nasal passage inflammation caused by infections or nasal polyps</p><p>** Brokerage <span>says </span>\"targeted education and commercial efforts\" <span>needed </span>to <span>increase Xhance </span>adoption among ENT and allergy specialists</p><p>** Current focus is on 3 mln CRS patients treated by ENT and allergy specialists, with potential to reach 7 mln in primary care and 20 mln overall in the U.S. - H.C. Wainwright </p><p>** Brokerage forecasts OPTN's 2024 net revenue at $77.3 mln</p><p>** OPTN declined 64.4% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-03 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects</title></head><body><p>** Brokerage H.C. Wainwright raises PT on <span>drug developer </span>OptiNose <span>OPTN.O</span> to $18 from $5, maintains \"buy\" rating</p><p>** New PT is a 168.7% upside to the stock's Thursday close</p><p>** On Dec. 26, 2024, OPTN announced <span>1-for-15</span> reverse stock split, citing the need to meet Nasdaq's minimum bid price requirement</p><p>** Brokerage says co's nasal spray, Xhance, provides a \"differentiated\" fluticasone propionate treatment for chronic rhinosinusitis <a href=\"https://laohu8.com/S/CRS\">$(CRS)$</a> patients</p><p>** CRS is a long-term sinus and nasal passage inflammation caused by infections or nasal polyps</p><p>** Brokerage <span>says </span>\"targeted education and commercial efforts\" <span>needed </span>to <span>increase Xhance </span>adoption among ENT and allergy specialists</p><p>** Current focus is on 3 mln CRS patients treated by ENT and allergy specialists, with potential to reach 7 mln in primary care and 20 mln overall in the U.S. - H.C. Wainwright </p><p>** Brokerage forecasts OPTN's 2024 net revenue at $77.3 mln</p><p>** OPTN declined 64.4% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250103:nL4N3NZ0OW:1","article_id":"2500115399","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500115399","pubTimestamp":1735911042,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects** Brokerage H.C. Wainwright raises PT on drug developer OptiNose OPTN.O to $18 from $5, maintains \"buy\" rating** New PT is a 168.7% upside to the stock's Thursday close** On Dec. 26, 2024, OPTN announced 1-for-15 reverse stock split, citing the need to meet Nasdaq's minimum bid price requirement** Brokerage says co's nasal spray, Xhance, provides a \"differentiated\" fluticasone propionate treatment for chronic rhinosinusitis  patients** CRS is a long-term sinus and nasal passage inflammation caused by infections or nasal polyps** Brokerage says \"targeted education and commercial efforts\" needed to increase Xhance adoption among ENT and allergy specialists** Current focus is on 3 mln CRS patients treated by ENT and allergy specialists, with potential to reach 7 mln in primary care and 20 mln overall in the U.S. - H.C. Wainwright ** Brokerage forecasts OPTN's 2024 net revenue at $77.3 mln** OPTN declined 64.4% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","OPTN":"Optinose Inc.","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"巴斯-H.C。Wainwright提高OptiNose PT的鼻喷雾剂前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"OPTN":0.9},"content_text":"BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects** Brokerage H.C. Wainwright raises PT on drug developer OptiNose OPTN.O to $18 from $5, maintains \"buy\" rating** New PT is a 168.7% upside to the stock's Thursday close** On Dec. 26, 2024, OPTN announced 1-for-15 reverse stock split, citing the need to meet Nasdaq's minimum bid price requirement** Brokerage says co's nasal spray, Xhance, provides a \"differentiated\" fluticasone propionate treatment for chronic rhinosinusitis $(CRS)$ patients** CRS is a long-term sinus and nasal passage inflammation caused by infections or nasal polyps** Brokerage says \"targeted education and commercial efforts\" needed to increase Xhance adoption among ENT and allergy specialists** Current focus is on 3 mln CRS patients treated by ENT and allergy specialists, with potential to reach 7 mln in primary care and 20 mln overall in the U.S. - H.C. Wainwright ** Brokerage forecasts OPTN's 2024 net revenue at $77.3 mln** OPTN declined 64.4% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}